0001567619-18-008589.txt : 20181226
0001567619-18-008589.hdr.sgml : 20181226
20181226163504
ACCESSION NUMBER: 0001567619-18-008589
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181224
FILED AS OF DATE: 20181226
DATE AS OF CHANGE: 20181226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gurney Austin
CENTRAL INDEX KEY: 0001553353
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35993
FILM NUMBER: 181252949
MAIL ADDRESS:
STREET 1: C/O ONCOMED PHARMACEUTICALS, INC.
STREET 2: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001302573
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 383572512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-995-8200
MAIL ADDRESS:
STREET 1: 800 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc1.xml
FORM 4
X0306
4
2018-12-24
1
0001302573
OncoMed Pharmaceuticals Inc
OMED
0001553353
Gurney Austin
C/O ONCOMED PHARMACEUTICALS, INC.
800 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
See Remarks
Common Stock
2018-12-24
4
S
0
11117
0.5999
D
66807
D
Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
This transaction was executed in multiple trades in prices ranging from $0.5601 to $0.6, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Chief Scientific Officer, Senior Vice President, Research
/s/ Alicia J. Hager, Attorney-in-Fact for Austin Gurney
2018-12-26